A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

A Three Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Minitab Modified Release Formulations in a Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A), the Pharmacokinetics of Escalating, Repeat Doses of a Selected Minitab Modified Release Prototype (Part B) , and the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Tablet Formulations in the Fed and Fasted State (Part C) in Healthy Participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03266172

Enrollment

Registered

2017-08-30

Start date

2017-09-27

Completion date

2018-11-21

Last updated

2021-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases

Keywords

immediate release tablet, GSK2982772, Modified release, minitablet

Brief summary

GSK2982772 is a first-in-class, highly selective, receptor-interacting protein-1 (RIP1) kinase inhibitor being developed for the treatment of inflammatory bowel disease, plaque psoriasis (PsO), rheumatoid arthritis (RA) and other disease conditions. PK data from the first time in human (FTIH) study for GSK2982772 showed that the half life of GSK2982772 was short (approximately 2 to 3 hours). A once daily (QD) formulation would be more convenient from a subject perspective and could offer the advantage of providing a flatter GSK2982772 concentration time profile. Following completion of Parts A and B, it was determined that the slowest minitab formulation provided a PK profile suitable for QD dosing but this formulation was susceptible to a food effect. This study will evaluate the pharmacokinetics of GSK2982772 following administration of different minitab MR formulations in a capsule relative to an IR reference tablet formulation, the pharmacokinetics of selected MR formulation in capsule following repeat doses for 3 days and to compare the pharmacokinetics of GSK2982772 following administration of MR tablet formulations in the fed and fasted state relative to an IR tablet formulation. The study is divided into three parts: Part A will be a non-randomized 6 periods, sequential, 6-way fixed sequence design in which up to 4 MR minitab formulations in a capsule will be evaluated. Periods 1, 2, and 3 will evaluate a slow MR release duration (nominally 24 hours), a fast MR release duration (nominally 10 hours), and IR tablet respectively. Periods 4, 5 and 6 will have flexible dose regimen and it will depend on the outcomes of Period 1 to 3. Subjects will be admitted to the clinic the previous day before dosing. Each in-patient period will consist of 3 days and 2 nights followed by a minimum washout period of 7 days between doses, for both Part A and C. In Part A and C, 16 healthy subjects will be enrolled such that at least 12 evaluable subjects complete the study. Part B will be an open-label, repeat dose study in which the selected MR minitab formulation in capsule will be evaluated. Each in-patient period will consist of 5 days and 4 nights. There will be a minimum of 7 days washout period between the last morning dose of one period and the first dose of the next period. In Part B, 10 healthy subjects will be enrolled such that at least 6 evaluable subjects complete the study. Part C of the study will be a non-randomised 6 period, sequential, fixed sequence crossover design in which MR tablet formulations will be evaluated. Periods 1 and 2 will evaluate single dose administration of a 240 milligram (mg) MR tablet and the 240 mg IR tablet (reference), respectively. Periods 3, 4, 5 and 6 will be flexible and the dosing regimen will be dependent on the outcome of Periods 1 and 2.

Interventions

DRUGGSK2982772 Modified Release

GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.

DRUGGSK2982772 Immediate Release

In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Part A of the study will be a non-randomized 6 period, sequential, 6-way fixed sequence design. Part B of the study will be a repeat dose study. Part C of the study will be a non-randomized 6 period, sequential, fixed sequence crossover design.

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Subject must be 18 to 65 years of age inclusive, at the time of signing the informed consent. * Subjects who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Body weight greater than and equal to 50 kilogram (kg) and body mass index within the range 19.0 to 32.0 kilogram per meter square (kg/m\^2) (inclusive). * A male subject must agree to use a highly effective contraception during the treatment period and for at least 90 days after the last dose of study treatment and refrain from donating sperm during this period. * A female subject is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive during the treatment period and for at least 30 days before and 30 days after the last dose of study treatment. * Capable of giving signed informed consent.

Exclusion criteria

* History of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data. * Parts A and C only: Any history of suicidal behavior within the past 6 months or any history of attempted suicide in a subject's lifetime. * Part B only: Subjects with current history of suicidal ideation behavior as measured using the columbia-suicide severity rating scale (C-SSRS) or a history of attempted suicide. * History of clinically significant psychiatric disorders as judged by the investigator. Depression requiring treatment in the last 2 years. * History of herpes zoster (shingles) reactivation. * History or diagnosis of obstructive sleep apnea. * History of a significant respiratory disorder. Childhood asthma that has fully resolved is permitted. * History or current evidence of febrile seizures, epilepsy, convulsions, significant head injury, or other significant neurologic conditions. * A positive diagnostic tuberculosis (TB) test at screening defined as a positive QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T spot test is indeterminate, the subject may have the test repeated once, but they will not be eligible for the study unless the second test is negative. * History of GI surgery (with exception of appendectomy). * History of cholecystectomy or gall stones. * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active. * ALT greater than 1.5 times upper limit of normal (ULN). * Bilirubin greater than 1.5 times ULN (isolated bilirubin greater than 1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35 percentage of total). * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome). * Corrected QT interval (QTc) greater than 450 millisecond (msec). * Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing (paracetamol/acetaminophen \[up to 2 gram (g) per day\], hormone replacement therapy and hormonal contraception are permitted). * Live or attenuated vaccine(s) within 30 days of enrolment, or plans to receive such vaccines during the study or plans to receive a vaccine within 30 days + 5 half-lives of the last dose of study medication. * Subject in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within a 56 day period; therefore donation or loss of greater than 400 mL of blood within the previous 3 months. * Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day. * Current enrolment or past participation within the last 3 months before signing of consent in this or any other clinical study involving an investigational study treatment or any other type of medical research. * Subjects who have previously been enrolled in this study. Subjects in Part A of this study are not permitted to participate in Part B. Subjects in Parts A or B of this study are not permitted to participate in Part C. * Current or history of renal disease or estimated glomerular filtration rate (GFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation calculation less than 60 mL/minutes(min)/1.73m\^2 at screening. * Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C antibody test result at screening or within 3 months prior to first dose. As potential for and magnitude of immunosuppression with this compound is unknown, subjects with presence of hepatitis B core antibody (HBcAb) should be excluded. Subjects positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded. * An elevated C-reactive protein (CRP) outside the normal reference range. * Part B only: A positive anti-nuclear antibody (ANA) outside the normal reference range. * Confirmed positive pre-study drug/alcohol screen. * Positive human immunodeficiency virus (HIV) antibody test. * Regular use of known drugs of abuse, or history of drug or alcohol abuse in the past 5 years. * Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of greater than 21 units for males or greater than 14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits. * Current use or history of regular use of tobacco- or nicotine-containing products within 6 months prior to screening. A carbon monoxide breath test reading of greater than 10 parts per million (ppm). * Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study. * Unwilling or unable to swallow multiple size 0-00 capsules as part of study participation. * Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator at screening. * Total cholesterol greater than or equal to 300 milligram/deciliter (mg/dL) (greater than or equal to 7.77 millimoles per liter \[mmol\]/L\]) or triglycerides greater than or equal to 250 mg/dL (greater than or equal to 2.82 mmol/L). * Subjects who are study site employees, or immediate family members of a study site or sponsor employee.

Design outcomes

Primary

Measure	Time frame	Description
Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.
AUC(0-inf) of GSK2982772 in MT Formulation :Part A	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).
Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)
AUC(0-t) of GSK2982772 in MT Formulation: Part A	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)
Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)
AUC(0-24) of GSK2982772 in MT Formulation: Part A	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)
Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)
AUC(0-12) of GSK2982772 in MT Formulation: Part A	Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)
Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for Cmax
Cmax of GSK2982772 in MT Formulation: Part A	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for Cmax
Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A	12 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for C12hour.
Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A	24 hours post-dose	Blood samples were collected from participants at indicated time points and analyzed for C24hour.
Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)	Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.
Frelformulation Based on AUC (0-24) of GSK2982772 in Part A	Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)	Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.
Frelformulation Based on Cmax of GSK2982772 in Part A	Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)	Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.
Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.
Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.
Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A	Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.
Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.
Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A	Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of Tmax.
Tmax of GSK2982772 in MT Formulation: Part A	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Tmax.
AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-inf)
AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-inf).
AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-t).
AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-t).
AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-24)
AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-24)
AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-12)
AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-12)
Cmax of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of Cmax
Cmax of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Cmax
C12 of GSK2982772 in Part C: Fasted State	12 hours post-dose	Blood samples was collected at indicated time point for analysis of C12
C24 of GSK2982772 in Part C: Fasted State	24 hours post-dose	Blood samples was collected at indicated time point for analysis of C24
Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.
Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.
Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State	Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.
Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State	Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.
Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)	Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.
Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State	Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)	Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.

Secondary

Measure	Time frame	Description
Change From Baseline in Respiration Rate: Part C	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.
Change From Baseline in Body Temperature: Part C	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.
AUC(0-24) of GSK2982772 in Part B	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3	Blood samples were collected at indicated time points for analysis of AUC (0-24)
Cmax of GSK2982772 in Part B	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3	Blood samples were collected at indicated time points for analysis of Cmax
Tmax of GSK2982772 in Part B	Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3	Blood samples were collected at indicated time points for analysis of Tmax
AUC (0-24) of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-24)
Cmax of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours	Blood samples were collected at indicated time points for analysis of Cmax
C12 of GSK2982772 After Meal in Part C	12 hours post-dose	Blood samples were collected at indicated time points for analysis of C12
AUC(0-t) of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-t)
AUC(0-inf) of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.
AUC(0-12) of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose	Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.
Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.
Frelformulation Based on Cmax of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.
Tmax of GSK2982772 After Meal in Part C	Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose	Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.
Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Up to Day 43	An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.
Number of Participants With AE and SAE in Part B	Up to Day 22	An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.
Number of Participants With AE and SAE in Part C	Up to Day 43	An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.
Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Up to Day 43	Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants Abnormal Urinalysis Dipstick Results: Part B	Up to Day 22	Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Up to Day 43	Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants Abnormal Urinalysis Dipstick Results: Part A	Up to Day 43	Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Up to Day 22	Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Up to Day 22	Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Up to Day 43	Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Up to Day 43	Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants Abnormal Urinalysis Dipstick Results: Part C	Up to Day 43	Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Up to Day 43	Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants Abnormal ECG Findings: Part B	Up to Day 22	Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
Number of Participants Abnormal ECG Findings: Part C	Up to Day 43	Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
Change From Baseline in Blood Pressure: Part A	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Heart Rate: Part A	Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Respiration Rate: Part A	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value
Change From Baseline in Body Temperature: Part A	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Blood Pressure: Part B	Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours	SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Heart Rate: Part B	Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours	Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Respiration Rate: Part B	Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours	Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value
Change From Baseline in Body Temperature: Part B	Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours	Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Blood Pressure: Part C	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
Change From Baseline in Heart Rate: Part C	Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours	Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.

Countries

United Kingdom

Participant flow

Recruitment details

This was an open label, 3-part, single and repeat dose study conducted in healthy participants to assess modified release (MR) minitablets (MT) in a capsule and MR monolithic matrix (MM) formulations of GSK2982772 compared to immediate release (IR) tablet formulation of GSK2982772.

Pre-assignment details

In this study, total 45 participants were enrolled.

Participants by arm

Arm	Count
MT-12hr Fasted/MT-8hr Fasted/IR Fasted/MT-12hr Fed (High Fat) Participants in Part A received a single dose of 120 mg GSK2982772 MR MT-12hour (hr) capsule (80% release at 12 hours) in fasted state in Period 1 followed by a single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state in Period 2. In Period 3, participants received a single oral dose of 120 milligram (mg) GSK2982772 (4x30 mg) IR tablet in fasted state followed by a single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal in Period 4. There was a washout period of 7 days between each treatment period. All doses were administered via the oral route with 240 milliliters (mL) of water.	19
MT 120mg Fasted/MT 240mg Fasted/ MT 300mg Fed (Standard) Participants in Part B received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 1 followed by once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 2. In Period 3, participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days. There was washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water.	10
MM240 Fast/IR240 Fast/MM480 Fast/MM480 Fed/MM480 DF/MM240 DF Participants in Part C received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted (Fast) state in Period 1 followed by a single dose of 240 mg GSK2982772 IR tablet in fasted state in Period 2. In Period 3, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. In Period 4, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state followed by a single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed \[DF\]) in Period 5. In Period 6, participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before high-fat breakfast (delayed fed). There was a washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water	16
Total	45

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Part A: Period 1(2 Days)	Withdrawal by Subject	1	0	0
Part A: Washout Period (7 Days)	Adverse Event	1	0	0
Part A: Washout Period (7 Days)	Withdrawal by Subject	1	0	0
Part B: Washout (7 Days)	Withdrawal by Subject	0	2	0
Part C Washout Period (7 Days)	Withdrawal by Subject	0	0	1

Baseline characteristics

Characteristic	MT-12hr Fasted/MT-8hr Fasted/IR Fasted/MT-12hr Fed (High Fat)	MT 120mg Fasted/MT 240mg Fasted/ MT 300mg Fed (Standard)	MM240 Fast/IR240 Fast/MM480 Fast/MM480 Fed/MM480 DF/MM240 DF	Total
Age, Continuous	49.2 Years STANDARD_DEVIATION 14.1	47.8 Years STANDARD_DEVIATION 13.43	45.3 Years STANDARD_DEVIATION 12.22	47.5 Years STANDARD_DEVIATION 13.12
Race/Ethnicity, Customized Asian - East Asian Heritage	1 Participants	0 Participants	1 Participants	2 Participants
Race/Ethnicity, Customized Asian - South East Asian Heritage	0 Participants	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized White - White/Caucasian/European Heritage	18 Participants	10 Participants	14 Participants	42 Participants
Sex: Female, Male Female	8 Participants	4 Participants	7 Participants	19 Participants
Sex: Female, Male Male	11 Participants	6 Participants	9 Participants	26 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk
deaths Total, all-cause mortality	0 / 16	1 / 16	0 / 13	0 / 16	0 / 10	0 / 10	0 / 6	0 / 15	0 / 15	0 / 16	0 / 16	0 / 15	0 / 14
other Total, other adverse events	4 / 16	5 / 16	1 / 13	2 / 16	1 / 10	3 / 10	1 / 6	3 / 15	3 / 15	3 / 16	4 / 16	2 / 15	1 / 14
serious Total, serious adverse events	0 / 16	1 / 16	0 / 13	0 / 16	0 / 10	0 / 10	0 / 6	0 / 15	0 / 15	0 / 16	0 / 16	0 / 15	0 / 14

Outcome results

Primary

Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A	5.967 Hours*microgram per milliliter	Geometric Coefficient of Variation 38.4

Primary

Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A	6.256 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.2

Primary

Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A	6.305 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.4

Primary

Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A	6.258 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.2

Primary

AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-12)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State	13.500 Hours*microgram per milliliter	Geometric Coefficient of Variation 26.3

Primary

AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-12)

Time frame: Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State	6.096 Hours*microgram per milliliter	Geometric Coefficient of Variation 32.8
Part A: MT-8hour 120mg Fasted	AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State	12.508 Hours*microgram per milliliter	Geometric Coefficient of Variation 40.1

Primary

AUC(0-12) of GSK2982772 in MT Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)

Time frame: Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-12) of GSK2982772 in MT Formulation: Part A	2.106 Hours*microgram per milliliter	Geometric Coefficient of Variation 45.1
Part A: MT-8hour 120mg Fasted	AUC(0-12) of GSK2982772 in MT Formulation: Part A	3.066 Hours*microgram per milliliter	Geometric Coefficient of Variation 47.7
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-12) of GSK2982772 in MT Formulation: Part A	3.573 Hours*microgram per milliliter	Geometric Coefficient of Variation 40.8

Primary

AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-24)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State	14.619 Hours*microgram per milliliter	Geometric Coefficient of Variation 25.7

Primary

AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-24)

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State	8.769 Hours*microgram per milliliter	Geometric Coefficient of Variation 30.9
Part A: MT-8hour 120mg Fasted	AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State	18.177 Hours*microgram per milliliter	Geometric Coefficient of Variation 31.5

Primary

AUC(0-24) of GSK2982772 in MT Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at specified time frame were analyzed

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-24) of GSK2982772 in MT Formulation: Part A	3.558 Hours*microgram per milliliter	Geometric Coefficient of Variation 43.6
Part A: MT-8hour 120mg Fasted	AUC(0-24) of GSK2982772 in MT Formulation: Part A	4.255 Hours*microgram per milliliter	Geometric Coefficient of Variation 49.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-24) of GSK2982772 in MT Formulation: Part A	4.580 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.5

Primary

AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-inf)

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population. Only those participants with data available at specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State	14.797 Hours*microgram per milliliter	Geometric Coefficient of Variation 26.3

Primary

AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-inf).

Time frame: Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State	13.417 Hours*microgram per milliliter	Geometric Coefficient of Variation 23.4
Part A: MT-8hour 120mg Fasted	AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State	22.493 Hours*microgram per milliliter	Geometric Coefficient of Variation 51.3

Primary

AUC(0-inf) of GSK2982772 in MT Formulation :Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-inf) of GSK2982772 in MT Formulation :Part A	3.852 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.4
Part A: MT-8hour 120mg Fasted	AUC(0-inf) of GSK2982772 in MT Formulation :Part A	4.482 Hours*microgram per milliliter	Geometric Coefficient of Variation 47.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-inf) of GSK2982772 in MT Formulation :Part A	5.314 Hours*microgram per milliliter	Geometric Coefficient of Variation 39.7

Primary

AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-t).

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State	14.621 Hours*microgram per milliliter	Geometric Coefficient of Variation 25.7

Primary

AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of AUC (0-t).

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State	9.676 Hours*microgram per milliliter	Geometric Coefficient of Variation 29.6
Part A: MT-8hour 120mg Fasted	AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State	20.009 Hours*microgram per milliliter	Geometric Coefficient of Variation 29.7

Primary

AUC(0-t) of GSK2982772 in MT Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-t) of GSK2982772 in MT Formulation: Part A	3.805 Hours*microgram per milliliter	Geometric Coefficient of Variation 42.3
Part A: MT-8hour 120mg Fasted	AUC(0-t) of GSK2982772 in MT Formulation: Part A	4.449 Hours*microgram per milliliter	Geometric Coefficient of Variation 49.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-t) of GSK2982772 in MT Formulation: Part A	4.720 Hours*microgram per milliliter	Geometric Coefficient of Variation 38.4

Primary

C12 of GSK2982772 in Part C: Fasted State

Blood samples was collected at indicated time point for analysis of C12

Time frame: 12 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	C12 of GSK2982772 in Part C: Fasted State	0.197 Microgram per milliliter	Geometric Coefficient of Variation 62.9
Part A: MT-8hour 120mg Fasted	C12 of GSK2982772 in Part C: Fasted State	0.346 Microgram per milliliter	Geometric Coefficient of Variation 41.7
Part A: MT-12hour 120mg Fed (High Fat)	C12 of GSK2982772 in Part C: Fasted State	0.671 Microgram per milliliter	Geometric Coefficient of Variation 42.3

Primary

C24 of GSK2982772 in Part C: Fasted State

Blood samples was collected at indicated time point for analysis of C24

Time frame: 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	C24 of GSK2982772 in Part C: Fasted State	0.025 Microgram per milliliter	Geometric Coefficient of Variation 54.9
Part A: MT-8hour 120mg Fasted	C24 of GSK2982772 in Part C: Fasted State	0.162 Microgram per milliliter	Geometric Coefficient of Variation 52.6
Part A: MT-12hour 120mg Fed (High Fat)	C24 of GSK2982772 in Part C: Fasted State	0.351 Microgram per milliliter	Geometric Coefficient of Variation 52.5

Primary

Cmax of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of Cmax

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Cmax of GSK2982772 for IR Formulation in Part C: Fasted State	2.938 Microgram per milliliter	Geometric Coefficient of Variation 25.2

Primary

Cmax of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of Cmax

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Cmax of GSK2982772 for MM Formulation in Part C: Fasted State	0.918 Microgram per milliliter	Geometric Coefficient of Variation 34.2
Part A: MT-8hour 120mg Fasted	Cmax of GSK2982772 for MM Formulation in Part C: Fasted State	2.010 Microgram per milliliter	Geometric Coefficient of Variation 50.1

Primary

Cmax of GSK2982772 in MT Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for Cmax

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Cmax of GSK2982772 in MT Formulation: Part A	0.277 Microgram per milliliter	Geometric Coefficient of Variation 58.8
Part A: MT-8hour 120mg Fasted	Cmax of GSK2982772 in MT Formulation: Part A	0.439 Microgram per milliliter	Geometric Coefficient of Variation 54.9
Part A: MT-12hour 120mg Fed (High Fat)	Cmax of GSK2982772 in MT Formulation: Part A	0.624 Microgram per milliliter	Geometric Coefficient of Variation 49.4

Primary

Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A

Blood samples were collected from participants at indicated time points and analyzed for C12hour.

Time frame: 12 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A	0.220 Microgram per milliliter	Geometric Coefficient of Variation 52.6
Part A: MT-8hour 120mg Fasted	Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A	0.209 Microgram per milliliter	Geometric Coefficient of Variation 56.2
Part A: MT-12hour 120mg Fed (High Fat)	Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A	0.208 Microgram per milliliter	Geometric Coefficient of Variation 53.1
Part A: IR 120mg Fasted	Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A	0.045 Microgram per milliliter	Geometric Coefficient of Variation 81.7

Primary

Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A

Blood samples were collected from participants at indicated time points and analyzed for C24hour.

Time frame: 24 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A	0.058 Microgram per milliliter	Geometric Coefficient of Variation 73.2
Part A: MT-8hour 120mg Fasted	Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A	0.046 Microgram per milliliter	Geometric Coefficient of Variation 69.5
Part A: MT-12hour 120mg Fed (High Fat)	Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A	0.030 Microgram per milliliter	Geometric Coefficient of Variation 46.6
Part A: IR 120mg Fasted	Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A	0.006 Microgram per milliliter	Geometric Coefficient of Variation 108.8

Primary

Frelformulation Based on AUC (0-24) of GSK2982772 in Part A

Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.

Time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on AUC (0-24) of GSK2982772 in Part A	68.18 Percentage bioavailability
Part A: MT-8hour 120mg Fasted	Frelformulation Based on AUC (0-24) of GSK2982772 in Part A	57.54 Percentage bioavailability

Primary

Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)

Population: PK Population. Only those participants with data available at the specified data points were analyzed

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State	59.98 Percentage bioavailability

Primary

Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)

Population: PK Population.

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State	66.18 Percentage bioavailability

Primary

Frelformulation Based on Cmax of GSK2982772 in Part A

Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.

Time frame: Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on Cmax of GSK2982772 in Part A	32.13 Percentage bioavailability
Part A: MT-8hour 120mg Fasted	Frelformulation Based on Cmax of GSK2982772 in Part A	20.39 Percentage bioavailability

Primary

Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A

Blood samples were collected from participants at indicated time points and analyzed for Cmax

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A	1.375 Microgram per milliliter	Geometric Coefficient of Variation 40.1

Primary

Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State	17.158 Ratio	Standard Deviation 7.9158

Primary

Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State	2.892 Ratio	Standard Deviation 1.2572
Part A: MT-8hour 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State	3.551 Ratio	Standard Deviation 2.2615

Primary

Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A	36.485 Ratio	Standard Deviation 20.9265

Primary

Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A	1.284 Ratio	Standard Deviation 0.2468
Part A: MT-8hour 120mg Fasted	Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A	2.265 Ratio	Standard Deviation 0.9119
Part A: MT-12hour 120mg Fed (High Fat)	Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A	3.240 Ratio	Standard Deviation 1.225

Primary

Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.

Time frame: Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose

Population: PK Population.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State	138.239 Ratio	Standard Deviation 76.3996

Primary

Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State	6.026 Ratio	Standard Deviation 2.1936
Part A: MT-8hour 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State	7.991 Ratio	Standard Deviation 10.6319

Primary

Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.

Time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A	312.851 Ratio	Standard Deviation 221.764

Primary

Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A

Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A	6.119 Ratio	Standard Deviation 5.1507
Part A: MT-8hour 120mg Fasted	Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A	10.790 Ratio	Standard Deviation 4.9019
Part A: MT-12hour 120mg Fed (High Fat)	Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A	22.915 Ratio	Standard Deviation 11.7978

Primary

Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A

Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.

Time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)

Population: PK Population. Only those participants with data available at specified time frame were analyzed.

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A	72.77 Percentage bioavailability
Part A: MT-8hour 120mg Fasted	Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A	60.53 Percentage bioavailability

Primary

Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A

Blood samples were collected at indicated time points for analysis of Tmax.

Time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Population: PK Population

Arm	Measure	Value (MEDIAN)
Part A: IR 120mg Fasted	Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A	2.000 Hours

Primary

Tmax of GSK2982772 in MT Formulation: Part A

Blood samples were collected at indicated time points for analysis of Tmax.

Time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEDIAN)
Part A: IR 120mg Fasted	Tmax of GSK2982772 in MT Formulation: Part A	10.000 Hours
Part A: MT-8hour 120mg Fasted	Tmax of GSK2982772 in MT Formulation: Part A	4.000 Hours
Part A: MT-12hour 120mg Fed (High Fat)	Tmax of GSK2982772 in MT Formulation: Part A	6.000 Hours

Secondary

AUC(0-12) of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.

Time frame: Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-12) of GSK2982772 After Meal in Part C	17.111 Hours*microgram/milliliter	Geometric Coefficient of Variation 45
Part A: MT-8hour 120mg Fasted	AUC(0-12) of GSK2982772 After Meal in Part C	10.241 Hours*microgram/milliliter	Geometric Coefficient of Variation 45.9
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-12) of GSK2982772 After Meal in Part C	6.771 Hours*microgram/milliliter	Geometric Coefficient of Variation 56.7

Secondary

AUC (0-24) of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of AUC (0-24)

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose

Population: PK Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC (0-24) of GSK2982772 After Meal in Part C	17.505 Hours*microgram/milliliter	Geometric Coefficient of Variation 29.5
Part A: MT-8hour 120mg Fasted	AUC (0-24) of GSK2982772 After Meal in Part C	8.734 Hours*microgram/milliliter	Geometric Coefficient of Variation 47.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC (0-24) of GSK2982772 After Meal in Part C	21.543 Hours*microgram/milliliter	Geometric Coefficient of Variation 39.2

Secondary

AUC(0-24) of GSK2982772 in Part B

Blood samples were collected at indicated time points for analysis of AUC (0-24)

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3

Population: PK Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-24) of GSK2982772 in Part B	Day 1, n=10, 9, 5	4.669 Hours*microgram/milliliter	Geometric Coefficient of Variation 26.5
Part A: IR 120mg Fasted	AUC(0-24) of GSK2982772 in Part B	Day 3, n=10, 10, 6	5.010 Hours*microgram/milliliter	Geometric Coefficient of Variation 32
Part A: MT-8hour 120mg Fasted	AUC(0-24) of GSK2982772 in Part B	Day 1, n=10, 9, 5	8.807 Hours*microgram/milliliter	Geometric Coefficient of Variation 34.3
Part A: MT-8hour 120mg Fasted	AUC(0-24) of GSK2982772 in Part B	Day 3, n=10, 10, 6	9.867 Hours*microgram/milliliter	Geometric Coefficient of Variation 30.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-24) of GSK2982772 in Part B	Day 1, n=10, 9, 5	9.662 Hours*microgram/milliliter	Geometric Coefficient of Variation 33.8
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-24) of GSK2982772 in Part B	Day 3, n=10, 10, 6	10.948 Hours*microgram/milliliter	Geometric Coefficient of Variation 37.7

Secondary

AUC(0-inf) of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-inf) of GSK2982772 After Meal in Part C	18.941 Hours*microgram/milliliter	Geometric Coefficient of Variation 36.5
Part A: MT-8hour 120mg Fasted	AUC(0-inf) of GSK2982772 After Meal in Part C	9.995 Hours*microgram/milliliter	Geometric Coefficient of Variation 62.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-inf) of GSK2982772 After Meal in Part C	24.367 Hours*microgram/milliliter	Geometric Coefficient of Variation 49.2

Secondary

AUC(0-t) of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of AUC (0-t)

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	AUC(0-t) of GSK2982772 After Meal in Part C	19.147 Hours*microgram/milliliter	Geometric Coefficient of Variation 28
Part A: MT-8hour 120mg Fasted	AUC(0-t) of GSK2982772 After Meal in Part C	9.202 Hours*microgram/milliliter	Geometric Coefficient of Variation 46.4
Part A: MT-12hour 120mg Fed (High Fat)	AUC(0-t) of GSK2982772 After Meal in Part C	22.712 Hours*microgram/milliliter	Geometric Coefficient of Variation 36.2

Secondary

C12 of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of C12

Time frame: 12 hours post-dose

Population: PK Population. Only participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	C12 of GSK2982772 After Meal in Part C	0.706 Microgram/milliliter	Geometric Coefficient of Variation 72.7
Part A: MT-8hour 120mg Fasted	C12 of GSK2982772 After Meal in Part C	0.739 Microgram/milliliter	Geometric Coefficient of Variation 37.1
Part A: MT-12hour 120mg Fed (High Fat)	C12 of GSK2982772 After Meal in Part C	0.317 Microgram/milliliter	Geometric Coefficient of Variation 49.5

Secondary

Change From Baseline in Blood Pressure: Part A

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 1, 12 hours, n=16,16, 13,16	-3.9 Millimeters of mercury	Standard Deviation 10.01
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 1, 12 hours, n=15,16, 13,16	-1.6 Millimeters of mercury	Standard Deviation 14.05
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 2, 24 hours, n=16,16, 13,16	2.1 Millimeters of mercury	Standard Deviation 8.51
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 2, 24 hours, n=16,16, 13,16	7.4 Millimeters of mercury	Standard Deviation 13.86
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP, Day 1, 2 hours, n=16,16, 13,16	0.3 Millimeters of mercury	Standard Deviation 7.33
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP, Day 1, 2 hours, n=16,16, 13,16	-1.4 Millimeters of mercury	Standard Deviation 13.46
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 2, 24 hours, n=16,16, 13,16	-2.7 Millimeters of mercury	Standard Deviation 9.76
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP, Day 1, 2 hours, n=16,16, 13,16	4.3 Millimeters of mercury	Standard Deviation 10.7
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 1, 12 hours, n=16,16, 13,16	-3.6 Millimeters of mercury	Standard Deviation 9.87
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP, Day 1, 2 hours, n=16,16, 13,16	3.0 Millimeters of mercury	Standard Deviation 8.12
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 2, 24 hours, n=16,16, 13,16	0.7 Millimeters of mercury	Standard Deviation 7.6
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 1, 12 hours, n=15,16, 13,16	-2.5 Millimeters of mercury	Standard Deviation 14.27
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	DBP,Day 2, 24 hours, n=16,16, 13,16	-1.7 Millimeters of mercury	Standard Deviation 7.79
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	SBP,Day 1, 12 hours, n=15,16, 13,16	-6.2 Millimeters of mercury	Standard Deviation 12.34
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	DBP, Day 1, 2 hours, n=16,16, 13,16	-1.8 Millimeters of mercury	Standard Deviation 7.81
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	SBP,Day 2, 24 hours, n=16,16, 13,16	-6.2 Millimeters of mercury	Standard Deviation 11.22
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	SBP, Day 1, 2 hours, n=16,16, 13,16	-0.2 Millimeters of mercury	Standard Deviation 16.53
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part A	DBP,Day 1, 12 hours, n=16,16, 13,16	-3.0 Millimeters of mercury	Standard Deviation 9.27
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 2, 24 hours, n=16,16, 13,16	-1.1 Millimeters of mercury	Standard Deviation 8.82
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP, Day 1, 2 hours, n=16,16, 13,16	-6.2 Millimeters of mercury	Standard Deviation 11.2
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 1, 12 hours, n=15,16, 13,16	-2.9 Millimeters of mercury	Standard Deviation 18.7
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	SBP,Day 2, 24 hours, n=16,16, 13,16	-3.9 Millimeters of mercury	Standard Deviation 14.11
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP, Day 1, 2 hours, n=16,16, 13,16	-4.4 Millimeters of mercury	Standard Deviation 8.94
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part A	DBP,Day 1, 12 hours, n=16,16, 13,16	-3.9 Millimeters of mercury	Standard Deviation 9.02

Secondary

Change From Baseline in Blood Pressure: Part B

SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, Pre-dose	2.6 Millimeters of mercury	Standard Deviation 8.57
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 12 hours	2.4 Millimeters of mercury	Standard Deviation 11.55
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 2, Pre-dose	-0.1 Millimeters of mercury	Standard Deviation 5.26
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 2, Pre-dose	-1.5 Millimeters of mercury	Standard Deviation 4.55
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 4, 24 hours	2.9 Millimeters of mercury	Standard Deviation 9.22
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 1, 12 hours	2.7 Millimeters of mercury	Standard Deviation 7.75
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 1, 12 hours	-1.7 Millimeters of mercury	Standard Deviation 5.5
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP, Day 1, 2 hours	2.4 Millimeters of mercury	Standard Deviation 7.31
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 2 hours	3.1 Millimeters of mercury	Standard Deviation 7
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, Pre-dose	-1.0 Millimeters of mercury	Standard Deviation 9.35
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 4, 24 hours	3.0 Millimeters of mercury	Standard Deviation 5.56
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP, Day 1, 2 hours	-0.5 Millimeters of mercury	Standard Deviation 7.4
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 2 hours	2.0 Millimeters of mercury	Standard Deviation 8.37
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 12 hours	-1.4 Millimeters of mercury	Standard Deviation 7.78
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, Pre-dose	1.3 Millimeters of mercury	Standard Deviation 6.65
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP, Day 1, 2 hours	5.4 Millimeters of mercury	Standard Deviation 7.37
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 1, 12 hours	1.5 Millimeters of mercury	Standard Deviation 8.86
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 2, Pre-dose	3.5 Millimeters of mercury	Standard Deviation 7.76
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, Pre-dose	1.1 Millimeters of mercury	Standard Deviation 5.09
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 2 hours	5.5 Millimeters of mercury	Standard Deviation 9.51
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 12 hours	7.4 Millimeters of mercury	Standard Deviation 14.17
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	SBP,Day 4, 24 hours	6.1 Millimeters of mercury	Standard Deviation 5.04
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP, Day 1, 2 hours	2.1 Millimeters of mercury	Standard Deviation 7.16
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 1, 12 hours	-2.2 Millimeters of mercury	Standard Deviation 4.59
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 2, Pre-dose	2.0 Millimeters of mercury	Standard Deviation 7.47
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 2 hours	4.0 Millimeters of mercury	Standard Deviation 5.31
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 12 hours	-1.4 Millimeters of mercury	Standard Deviation 5.72
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part B	DBP,Day 4, 24 hours	4.6 Millimeters of mercury	Standard Deviation 4.77
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 12 hours	-2.5 Millimeters of mercury	Standard Deviation 2.81
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 2, Pre-dose	-2.7 Millimeters of mercury	Standard Deviation 6.56
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 2 hours	-3.3 Millimeters of mercury	Standard Deviation 9.14
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, Pre-dose	-0.7 Millimeters of mercury	Standard Deviation 14.09
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, Pre-dose	1.3 Millimeters of mercury	Standard Deviation 4.5
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 2, Pre-dose	1.8 Millimeters of mercury	Standard Deviation 6.62
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP, Day 1, 2 hours	1.2 Millimeters of mercury	Standard Deviation 7.08
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 3, 2 hours	-5.8 Millimeters of mercury	Standard Deviation 3.87
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 1, 12 hours	1.0 Millimeters of mercury	Standard Deviation 10.73
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP, Day 1, 2 hours	-4.0 Millimeters of mercury	Standard Deviation 4.2
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 4, 24 hours	6.0 Millimeters of mercury	Standard Deviation 11.24
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 4, 24 hours	1.3 Millimeters of mercury	Standard Deviation 6.65
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	DBP,Day 1, 12 hours	-5.7 Millimeters of mercury	Standard Deviation 4.03
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part B	SBP,Day 3, 12 hours	3.8 Millimeters of mercury	Standard Deviation 8.21

Secondary

Change From Baseline in Blood Pressure: Part C

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	-3.3 Millimeters of mercury	Standard Deviation 7.93
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	-3.1 Millimeters of mercury	Standard Deviation 10.04
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	4.9 Millimeters of mercury	Standard Deviation 8.02
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	-0.1 Millimeters of mercury	Standard Deviation 7.41
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	-2.1 Millimeters of mercury	Standard Deviation 7.23
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	0.4 Millimeters of mercury	Standard Deviation 7.21
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	-2.6 Millimeters of mercury	Standard Deviation 8.34
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	-0.7 Millimeters of mercury	Standard Deviation 6.43
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	1.0 Millimeters of mercury	Standard Deviation 4.88
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	-0.6 Millimeters of mercury	Standard Deviation 7.5
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	-1.4 Millimeters of mercury	Standard Deviation 6.71
Part A: MT-8hour 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	-1.1 Millimeters of mercury	Standard Deviation 6.36
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	-0.5 Millimeters of mercury	Standard Deviation 6.64
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	-3.1 Millimeters of mercury	Standard Deviation 6.53
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	2.0 Millimeters of mercury	Standard Deviation 6.92
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	-1.6 Millimeters of mercury	Standard Deviation 8.39
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	-0.6 Millimeters of mercury	Standard Deviation 6.16
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	1.4 Millimeters of mercury	Standard Deviation 12.06
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	-4.3 Millimeters of mercury	Standard Deviation 6.94
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	0.1 Millimeters of mercury	Standard Deviation 10.81
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	-3.1 Millimeters of mercury	Standard Deviation 8.5
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	2.8 Millimeters of mercury	Standard Deviation 6.37
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	-0.6 Millimeters of mercury	Standard Deviation 8.02
Part A: IR 120mg Fasted	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	-4.9 Millimeters of mercury	Standard Deviation 9.18
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	1.1 Millimeters of mercury	Standard Deviation 16.02
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	-3.7 Millimeters of mercury	Standard Deviation 9.61
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	-7.3 Millimeters of mercury	Standard Deviation 14.92
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	2.6 Millimeters of mercury	Standard Deviation 10.84
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	-0.6 Millimeters of mercury	Standard Deviation 7.88
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	0.7 Millimeters of mercury	Standard Deviation 7.49
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	DBP, Day 1, 2 hours	-1.9 Millimeters of mercury	Standard Deviation 5.5
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	SBP,Day2, 24 hours	-7.5 Millimeters of mercury	Standard Deviation 10.58
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	DBP,Day1, 12 hours	0.0 Millimeters of mercury	Standard Deviation 8.38
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	DBP,Day2, 24 hours	2.4 Millimeters of mercury	Standard Deviation 6.21
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	SBP,Day1, 12 hours	0.9 Millimeters of mercury	Standard Deviation 16.03
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Blood Pressure: Part C	SBP, Day 1, 2 hours	-0.2 Millimeters of mercury	Standard Deviation 11.44

Secondary

Change From Baseline in Body Temperature: Part A

Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 2 hours	0.02 Degree Celsius	Standard Deviation 0.152
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 2, 24 hours	0.04 Degree Celsius	Standard Deviation 0.182
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 12 hours	0.07 Degree Celsius	Standard Deviation 0.139
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 2 hours	0.18 Degree Celsius	Standard Deviation 0.18
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 2, 24 hours	0.07 Degree Celsius	Standard Deviation 0.095
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 12 hours	-0.04 Degree Celsius	Standard Deviation 0.145
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part A	Day 1, 12 hours	0.13 Degree Celsius	Standard Deviation 0.118
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part A	Day 1, 2 hours	0.05 Degree Celsius	Standard Deviation 0.145
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part A	Day 2, 24 hours	0.12 Degree Celsius	Standard Deviation 0.114
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 2 hours	0.14 Degree Celsius	Standard Deviation 0.126
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 2, 24 hours	0.12 Degree Celsius	Standard Deviation 0.161
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part A	Day 1, 12 hours	0.11 Degree Celsius	Standard Deviation 0.173

Secondary

Change From Baseline in Body Temperature: Part B

Time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 1, 12 hours	0.06 Degree Celsius	Standard Deviation 0.181
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, 2 hours	-0.03 Degree Celsius	Standard Deviation 0.149
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, Pre-dose	0.04 Degree Celsius	Standard Deviation 0.135
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 1, 2 hours	0.03 Degree Celsius	Standard Deviation 0.298
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 4, 24 hours	0.04 Degree Celsius	Standard Deviation 0.171
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, 12 hours	0.01 Degree Celsius	Standard Deviation 0.191
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 2, Pre-dose	0.04 Degree Celsius	Standard Deviation 0.184
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, Pre-dose	0.07 Degree Celsius	Standard Deviation 0.271
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 1, 2 hours	-0.01 Degree Celsius	Standard Deviation 0.233
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 1, 12 hours	0.08 Degree Celsius	Standard Deviation 0.274
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 2, Pre-dose	-0.04 Degree Celsius	Standard Deviation 0.158
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, 2 hours	0.01 Degree Celsius	Standard Deviation 0.26
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 3, 12 hours	0.05 Degree Celsius	Standard Deviation 0.242
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part B	Day 4, 24 hours	0.11 Degree Celsius	Standard Deviation 0.247
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 3, 2 hours	-0.08 Degree Celsius	Standard Deviation 0.147
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 1, 12 hours	0.07 Degree Celsius	Standard Deviation 0.082
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 4, 24 hours	0.00 Degree Celsius	Standard Deviation 0.089
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 3, 12 hours	0.05 Degree Celsius	Standard Deviation 0.138
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 3, Pre-dose	0.23 Degree Celsius	Standard Deviation 0.151
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 2, Pre-dose	0.12 Degree Celsius	Standard Deviation 0.133
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part B	Day 1, 2 hours	0.00 Degree Celsius	Standard Deviation 0.11

Secondary

Change From Baseline in Body Temperature: Part C

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	0.02 Degree Celsius	Standard Deviation 0.197
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	-0.10 Degree Celsius	Standard Deviation 0.245
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	-0.04 Degree Celsius	Standard Deviation 0.256
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	-0.11 Degree Celsius	Standard Deviation 0.229
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	-0.05 Degree Celsius	Standard Deviation 0.192
Part A: MT-8hour 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	0.15 Degree Celsius	Standard Deviation 0.261
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	-0.00 Degree Celsius	Standard Deviation 0.239
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	-0.07 Degree Celsius	Standard Deviation 0.215
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	-0.05 Degree Celsius	Standard Deviation 0.271
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	0.12 Degree Celsius	Standard Deviation 0.307
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	0.23 Degree Celsius	Standard Deviation 0.275
Part A: IR 120mg Fasted	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	0.10 Degree Celsius	Standard Deviation 0.278
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	-0.14 Degree Celsius	Standard Deviation 0.241
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	0.01 Degree Celsius	Standard Deviation 0.228
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	-0.09 Degree Celsius	Standard Deviation 0.269
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Body Temperature: Part C	Day 2, 24 hours	-0.01 Degree Celsius	Standard Deviation 0.241
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Body Temperature: Part C	Day 1, 12 hours	-0.10 Degree Celsius	Standard Deviation 0.266
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Body Temperature: Part C	Day 1, 2 hours	0.10 Degree Celsius	Standard Deviation 0.301

Secondary

Change From Baseline in Heart Rate: Part A

Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame: Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 2 hours	-4.4 Beats per minute	Standard Deviation 5.11
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 2, 24 hours	1.5 Beats per minute	Standard Deviation 9.41
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 12 hours	4.8 Beats per minute	Standard Deviation 6.06
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 2 hours	-0.3 Beats per minute	Standard Deviation 4.88
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 2, 24 hours	-2.1 Beats per minute	Standard Deviation 6.31
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 12 hours	5.2 Beats per minute	Standard Deviation 3.94
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part A	Day 1, 12 hours	5.8 Beats per minute	Standard Deviation 5.57
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part A	Day 1, 2 hours	-2.5 Beats per minute	Standard Deviation 7.62
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part A	Day 2, 24 hours	0.6 Beats per minute	Standard Deviation 7.14
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 2 hours	3.9 Beats per minute	Standard Deviation 7.48
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 2, 24 hours	0.9 Beats per minute	Standard Deviation 7.62
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part A	Day 1, 12 hours	7.5 Beats per minute	Standard Deviation 9.93

Secondary

Change From Baseline in Heart Rate: Part B

Time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 1, 12 hours	10.0 Beats per minute	Standard Deviation 4
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, 2 hours	1.2 Beats per minute	Standard Deviation 5.37
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, Pre-dose	2.3 Beats per minute	Standard Deviation 4.74
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 1, 2 hours	0.0 Beats per minute	Standard Deviation 5.5
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 4, 24 hours	4.7 Beats per minute	Standard Deviation 8.64
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, 12 hours	8.6 Beats per minute	Standard Deviation 4.58
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 2, Pre-dose	-0.1 Beats per minute	Standard Deviation 4.68
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, Pre-dose	-0.1 Beats per minute	Standard Deviation 5.88
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 1, 2 hours	-2.4 Beats per minute	Standard Deviation 5.38
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 1, 12 hours	8.8 Beats per minute	Standard Deviation 5.22
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 2, Pre-dose	-0.8 Beats per minute	Standard Deviation 6.37
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, 2 hours	-0.3 Beats per minute	Standard Deviation 5.36
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 3, 12 hours	10.6 Beats per minute	Standard Deviation 7.26
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part B	Day 4, 24 hours	6.7 Beats per minute	Standard Deviation 10.01
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 3, 2 hours	4.0 Beats per minute	Standard Deviation 2.28
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 1, 12 hours	10.5 Beats per minute	Standard Deviation 3.78
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 4, 24 hours	0.3 Beats per minute	Standard Deviation 2.58
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 3, 12 hours	7.7 Beats per minute	Standard Deviation 5.28
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 3, Pre-dose	1.5 Beats per minute	Standard Deviation 5.43
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 2, Pre-dose	-1.8 Beats per minute	Standard Deviation 2.71
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part B	Day 1, 2 hours	7.3 Beats per minute	Standard Deviation 6.89

Secondary

Change From Baseline in Heart Rate: Part C

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	6.8 Beats per minute	Standard Deviation 6.2
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	2.1 Beats per minute	Standard Deviation 6.94
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	1.8 Beats per minute	Standard Deviation 5.44
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	6.5 Beats per minute	Standard Deviation 9.73
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	-5.3 Beats per minute	Standard Deviation 6.19
Part A: MT-8hour 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	0.1 Beats per minute	Standard Deviation 6.41
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	11.2 Beats per minute	Standard Deviation 9.65
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	0.0 Beats per minute	Standard Deviation 6.86
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	-0.4 Beats per minute	Standard Deviation 3.77
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	10.3 Beats per minute	Standard Deviation 6.94
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	7.3 Beats per minute	Standard Deviation 6.56
Part A: IR 120mg Fasted	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	0.4 Beats per minute	Standard Deviation 5.8
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	9.3 Beats per minute	Standard Deviation 8.28
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	8.2 Beats per minute	Standard Deviation 5.72
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	-0.9 Beats per minute	Standard Deviation 6.19
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Heart Rate: Part C	Day 1, 2 hours	8.2 Beats per minute	Standard Deviation 7.32
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Heart Rate: Part C	Day 2, 24 hours	1.6 Beats per minute	Standard Deviation 7.74
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Heart Rate: Part C	Day 1, 12 hours	8.6 Beats per minute	Standard Deviation 6.99

Secondary

Change From Baseline in Respiration Rate: Part A

Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 2 hours	-0.4 Breaths per minute	Standard Deviation 1.67
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 2, 24 hours	1.3 Breaths per minute	Standard Deviation 2.15
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 12 hours	-0.6 Breaths per minute	Standard Deviation 1.71
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 2 hours	0.8 Breaths per minute	Standard Deviation 1.65
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 2, 24 hours	-0.1 Breaths per minute	Standard Deviation 1.54
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 12 hours	-0.1 Breaths per minute	Standard Deviation 1.82
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part A	Day 1, 12 hours	-0.2 Breaths per minute	Standard Deviation 1.21
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part A	Day 1, 2 hours	0.0 Breaths per minute	Standard Deviation 1
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part A	Day 2, 24 hours	-1.5 Breaths per minute	Standard Deviation 1.51
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 2 hours	-1.5 Breaths per minute	Standard Deviation 2.5
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 2, 24 hours	-1.4 Breaths per minute	Standard Deviation 2.13
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part A	Day 1, 12 hours	-2.4 Breaths per minute	Standard Deviation 2.63

Secondary

Change From Baseline in Respiration Rate: Part B

Time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 1, 12 hours	-0.1 Breaths per minute	Standard Deviation 1.37
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, 2 hours	-1.3 Breaths per minute	Standard Deviation 2.36
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, Pre-dose	-0.7 Breaths per minute	Standard Deviation 2.67
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 1, 2 hours	0.5 Breaths per minute	Standard Deviation 2.27
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 4, 24 hours	-0.8 Breaths per minute	Standard Deviation 1.87
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, 12 hours	0.3 Breaths per minute	Standard Deviation 3.02
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 2, Pre-dose	-0.3 Breaths per minute	Standard Deviation 1.49
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, Pre-dose	-0.5 Breaths per minute	Standard Deviation 1.43
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 1, 2 hours	-2.0 Breaths per minute	Standard Deviation 2
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 1, 12 hours	-2.5 Breaths per minute	Standard Deviation 2.17
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 2, Pre-dose	-0.5 Breaths per minute	Standard Deviation 2.07
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, 2 hours	-1.0 Breaths per minute	Standard Deviation 2.21
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 3, 12 hours	-1.3 Breaths per minute	Standard Deviation 2.16
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part B	Day 4, 24 hours	-1.0 Breaths per minute	Standard Deviation 1.89
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 3, 2 hours	-0.7 Breaths per minute	Standard Deviation 2.16
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 1, 12 hours	-1.5 Breaths per minute	Standard Deviation 2.35
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 4, 24 hours	-0.3 Breaths per minute	Standard Deviation 2.42
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 3, 12 hours	-0.8 Breaths per minute	Standard Deviation 1.33
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 3, Pre-dose	1.5 Breaths per minute	Standard Deviation 2.26
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 2, Pre-dose	-0.5 Breaths per minute	Standard Deviation 2.74
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part B	Day 1, 2 hours	-1.2 Breaths per minute	Standard Deviation 3.54

Secondary

Change From Baseline in Respiration Rate: Part C

Time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	1.1 Breaths per minute	Standard Deviation 2.59
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	1.7 Breaths per minute	Standard Deviation 3.37
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	1.6 Breaths per minute	Standard Deviation 3.25
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	1.0 Breaths per minute	Standard Deviation 2.85
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	0.6 Breaths per minute	Standard Deviation 2.03
Part A: MT-8hour 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	0.4 Breaths per minute	Standard Deviation 3.07
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	0.6 Breaths per minute	Standard Deviation 2.66
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	0.9 Breaths per minute	Standard Deviation 2.9
Part A: MT-12hour 120mg Fed (High Fat)	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	0.6 Breaths per minute	Standard Deviation 4
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	-1.1 Breaths per minute	Standard Deviation 2.9
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	-1.1 Breaths per minute	Standard Deviation 2.95
Part A: IR 120mg Fasted	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	-2.2 Breaths per minute	Standard Deviation 2.66
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	-0.3 Breaths per minute	Standard Deviation 2.61
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	1.8 Breaths per minute	Standard Deviation 1.74
Part C:MM-12h 480mg Delayed Fed(Standard)	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	1.8 Breaths per minute	Standard Deviation 2.31
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Respiration Rate: Part C	Day 1, 2 hours	0.1 Breaths per minute	Standard Deviation 2.76
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Respiration Rate: Part C	Day 2, 24 hours	0.4 Breaths per minute	Standard Deviation 3.34
Part C: MM-12h 240mg Delayed Fed(High Fat)	Change From Baseline in Respiration Rate: Part C	Day 1, 12 hours	0.5 Breaths per minute	Standard Deviation 1.51

Secondary

Cmax of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of Cmax

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours

Population: PK Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Cmax of GSK2982772 After Meal in Part C	1.547 Microgram/milliliter	Geometric Coefficient of Variation 40.8
Part A: MT-8hour 120mg Fasted	Cmax of GSK2982772 After Meal in Part C	1.064 Microgram/milliliter	Geometric Coefficient of Variation 62.6
Part A: MT-12hour 120mg Fed (High Fat)	Cmax of GSK2982772 After Meal in Part C	3.151 Microgram/milliliter	Geometric Coefficient of Variation 32.5

Secondary

Cmax of GSK2982772 in Part B

Blood samples were collected at indicated time points for analysis of Cmax

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3

Population: PK Population.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part A: IR 120mg Fasted	Cmax of GSK2982772 in Part B	Day 1	0.417 Microgram/milliliter	Geometric Coefficient of Variation 25.5
Part A: IR 120mg Fasted	Cmax of GSK2982772 in Part B	Day 3	0.398 Microgram/milliliter	Geometric Coefficient of Variation 32.9
Part A: MT-8hour 120mg Fasted	Cmax of GSK2982772 in Part B	Day 1	0.707 Microgram/milliliter	Geometric Coefficient of Variation 44.7
Part A: MT-8hour 120mg Fasted	Cmax of GSK2982772 in Part B	Day 3	0.794 Microgram/milliliter	Geometric Coefficient of Variation 35.7
Part A: MT-12hour 120mg Fed (High Fat)	Cmax of GSK2982772 in Part B	Day 1	0.888 Microgram/milliliter	Geometric Coefficient of Variation 14.1
Part A: MT-12hour 120mg Fed (High Fat)	Cmax of GSK2982772 in Part B	Day 3	1.080 Microgram/milliliter	Geometric Coefficient of Variation 40.4

Secondary

Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A

Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A	123.64 Percentage bioavailability

Secondary

Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C	94.69 Percentage bioavailability
Part A: MT-8hour 120mg Fasted	Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C	113.51 Percentage bioavailability
Part A: MT-12hour 120mg Fed (High Fat)	Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C	91.13 Percentage bioavailability

Secondary

Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A

Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population. Only those participants with data available at specified timepoint were analyzed

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A	225.07 Percentage bioavailability

Secondary

Frelformulation Based on Cmax of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population

Arm	Measure	Value (NUMBER)
Part A: IR 120mg Fasted	Frelformulation Based on Cmax of GSK2982772 After Meal in Part C	76.56 Percentage bioavailability
Part A: MT-8hour 120mg Fasted	Frelformulation Based on Cmax of GSK2982772 After Meal in Part C	156.77 Percentage bioavailability
Part A: MT-12hour 120mg Fed (High Fat)	Frelformulation Based on Cmax of GSK2982772 After Meal in Part C	113.81 Percentage bioavailability

Secondary

Number of Participants Abnormal ECG Findings: Part B

Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 22

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part B	Abnormal, not clinically significant	4 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part B	Abnormal, clinically significant	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal ECG Findings: Part B	Abnormal, not clinically significant	4 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal ECG Findings: Part B	Abnormal, clinically significant	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal ECG Findings: Part B	Abnormal, not clinically significant	2 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal ECG Findings: Part B	Abnormal, clinically significant	0 Participants

Secondary

Number of Participants Abnormal ECG Findings: Part C

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	1 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	4 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	7 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	5 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	6 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, not clinically significant	3 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants Abnormal ECG Findings: Part C	Abnormal, clinically significant	0 Participants

Secondary

Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A

Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, not clinically significant	6 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, clinically significant	1 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, clinically significant	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, not clinically significant	8 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, not clinically significant	9 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, clinically significant	0 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, not clinically significant	9 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A	Abnormal, clinically significant	0 Participants

Secondary

Number of Participants Abnormal Urinalysis Dipstick Results: Part A

Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part A	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part A	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal Urinalysis Dipstick Results: Part A	0 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part A	0 Participants

Secondary

Number of Participants Abnormal Urinalysis Dipstick Results: Part B

Time frame: Up to Day 22

Population: Safety Population

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part B	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part B	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal Urinalysis Dipstick Results: Part B	0 Participants

Secondary

Number of Participants Abnormal Urinalysis Dipstick Results: Part C

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants
Part A: IR 120mg Fasted	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants Abnormal Urinalysis Dipstick Results: Part C	0 Participants

Secondary

Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A

An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any AEs	4 Participants
Part A: IR 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any SAEs	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any SAEs	1 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any AEs	5 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any AEs	1 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any SAEs	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any AEs	2 Participants
Part A: IR 120mg Fasted	Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A	Any SAEs	0 Participants

Secondary

Number of Participants With AE and SAE in Part B

Time frame: Up to Day 22

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part B	Any AEs	1 Participants
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part B	Any SAEs	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With AE and SAE in Part B	Any AEs	3 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With AE and SAE in Part B	Any SAEs	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With AE and SAE in Part B	Any AEs	1 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With AE and SAE in Part B	Any SAEs	0 Participants

Secondary

Number of Participants With AE and SAE in Part C

An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part C	Any AEs	3 Participants
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With AE and SAE in Part C	Any AEs	3 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With AE and SAE in Part C	Any AEs	3 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part C	Any AEs	4 Participants
Part A: IR 120mg Fasted	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With AE and SAE in Part C	Any AEs	2 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With AE and SAE in Part C	Any AEs	1 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With AE and SAE in Part C	Any SAEs	0 Participants

Secondary

Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A

Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, normal or no change16	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, high	1 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, normal or no change16	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, normal or no change16	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, high	1 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, normal or no change16	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Sodium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Total Bilirubin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Albumin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	AST, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALP, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	ALT, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Creatinine, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Glucose, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Potassium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A	Calcium, high	0 Participants

Secondary

Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B

Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 22

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, normal or no change	10 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Total Bilirubin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Calcium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Glucose, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Albumin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Sodium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Potassium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALP, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	Creatinine, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	AST, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B	ALT, low	0 Participants

Secondary

Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C

Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	15 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	15 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	1 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	1 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	14 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, high	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Glucose, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALT, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Calcium, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Total Bilirubin, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Creatinine, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Potassium, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	AST, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Albumin, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	ALP, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C	Sodium, low	0 Participants

Secondary

Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A

Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, low	1 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, low	1 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, normal or no change	16 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, normal or no change	13 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, low	2 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, normal or no change	11 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, low	1 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, normal or no change	12 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Platelet count, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hematocrit, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Total Neutrophils, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	WBC, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Lymphocytes, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A	Hemoglobin, high	0 Participants

Secondary

Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B

Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 22

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, normal or no change	10 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, normal or no change	10 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Lymphocytes, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Platelet count, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hematocrit, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Hemoglobin, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	Total Neutrophils, normal or no change	6 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B	WBC, normal or no change	6 Participants

Secondary

Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C

Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.

Time frame: Up to Day 43

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	15 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	15 Participants
Part A: MT-8hour 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	16 Participants
Part A: MT-12hour 120mg Fed (High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	16 Participants
Part A: IR 120mg Fasted	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	15 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part C:MM-12h 480mg Delayed Fed(Standard)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	WBC, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, normal or no change	14 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hemoglobin, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Hematocrit, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Lymphocytes, low	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Platelet count, high	0 Participants
Part C: MM-12h 240mg Delayed Fed(High Fat)	Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C	Total Neutrophils, high	0 Participants

Secondary

Tmax of GSK2982772 After Meal in Part C

Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.

Time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose

Population: PK Population.

Arm	Measure	Value (MEDIAN)
Part A: IR 120mg Fasted	Tmax of GSK2982772 After Meal in Part C	4.000 Hours
Part A: MT-8hour 120mg Fasted	Tmax of GSK2982772 After Meal in Part C	4.000 Hours
Part A: MT-12hour 120mg Fed (High Fat)	Tmax of GSK2982772 After Meal in Part C	5.017 Hours

Secondary

Tmax of GSK2982772 in Part B

Blood samples were collected at indicated time points for analysis of Tmax

Time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3

Population: PK Population.

Arm	Measure	Group	Value (MEDIAN)
Part A: IR 120mg Fasted	Tmax of GSK2982772 in Part B	Day 1	4.058 Hours
Part A: IR 120mg Fasted	Tmax of GSK2982772 in Part B	Day 3	4.000 Hours
Part A: MT-8hour 120mg Fasted	Tmax of GSK2982772 in Part B	Day 1	4.067 Hours
Part A: MT-8hour 120mg Fasted	Tmax of GSK2982772 in Part B	Day 3	5.025 Hours
Part A: MT-12hour 120mg Fed (High Fat)	Tmax of GSK2982772 in Part B	Day 1	4.000 Hours
Part A: MT-12hour 120mg Fed (High Fat)	Tmax of GSK2982772 in Part B	Day 3	4.000 Hours

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A

Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A

Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A

Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A

AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State

AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State

AUC(0-12) of GSK2982772 in MT Formulation: Part A

AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State

AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State

AUC(0-24) of GSK2982772 in MT Formulation: Part A

AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State

AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State

AUC(0-inf) of GSK2982772 in MT Formulation :Part A

AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State

AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State

AUC(0-t) of GSK2982772 in MT Formulation: Part A

C12 of GSK2982772 in Part C: Fasted State

C24 of GSK2982772 in Part C: Fasted State

Cmax of GSK2982772 for IR Formulation in Part C: Fasted State

Cmax of GSK2982772 for MM Formulation in Part C: Fasted State

Cmax of GSK2982772 in MT Formulation: Part A

Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A

Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A

Frelformulation Based on AUC (0-24) of GSK2982772 in Part A

Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State

Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State

Frelformulation Based on Cmax of GSK2982772 in Part A

Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A

Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State

Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State

Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A

Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A

Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State

Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State

Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A

Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A

Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A

Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A

Tmax of GSK2982772 in MT Formulation: Part A

AUC(0-12) of GSK2982772 After Meal in Part C

AUC (0-24) of GSK2982772 After Meal in Part C

AUC(0-24) of GSK2982772 in Part B

AUC(0-inf) of GSK2982772 After Meal in Part C

AUC(0-t) of GSK2982772 After Meal in Part C

C12 of GSK2982772 After Meal in Part C

Change From Baseline in Blood Pressure: Part A

Change From Baseline in Blood Pressure: Part B

Change From Baseline in Blood Pressure: Part C

Change From Baseline in Body Temperature: Part A

Change From Baseline in Body Temperature: Part B

Change From Baseline in Body Temperature: Part C

Change From Baseline in Heart Rate: Part A

Change From Baseline in Heart Rate: Part B

Change From Baseline in Heart Rate: Part C

Change From Baseline in Respiration Rate: Part A

Change From Baseline in Respiration Rate: Part B